Summit Therapeutics Inc. Company Investigated By The Portnoy Law Firm

LOS ANGELES, June 06, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. (“Summit” or“the Company”) (NASDAQ: SMMT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Summit investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : ..., to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

On May 30, 2025, Summit issued a press release announcing topline results from its Phase III clinical trial, HARMONi-the first global Phase III study evaluating ivonescimab. While the combination of ivonescimab and chemotherapy reduced the risk of disease progression or death by 48% compared to chemotherapy alone, the treatment did not demonstrate a statistically significant improvement in overall survival, which measures the length of time patients live regardless of cause of death.

Following this announcement, Summit's stock price declined by $7.99 per share, or approximately 30.5%, closing at $18.22 on May 30, 2025.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
...
310-692-8883

Attorney Advertising

MENAFN06062025004107003653ID1109646797